Helen Heyerdahl
Overview
Explore the profile of Helen Heyerdahl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malenge M, Maaland A, Repetto-Llamazares A, Middleton B, Nijland M, Visser L, et al.
PLoS One
. 2022 Apr;
17(4):e0267543.
PMID: 35486574
Background And Purpose: PARP inhibitors have been shown to increase the efficacy of radiotherapy in preclinical models. Radioimmunotherapy results in selective radiation cytotoxicity of targeted tumour cells. Here we investigate...
2.
Giesen D, Lub-de Hooge M, Nijland M, Heyerdahl H, Dahle J, de Vries E, et al.
Sci Rep
. 2022 Apr;
12(1):6286.
PMID: 35428777
[Lu]Lu-DOTA-NNV003, a radioimmunoconjugate targeting CD37, is developed as novel radioimmunotherapy (RIT) treatment for patients with B cell non-Hodgkin's lymphoma (NHL). Since patients are at risk for developing hematological toxicities due...
3.
Maaland A, Saidi A, Torgue J, Heyerdahl H, Stallons T, Kolstad A, et al.
PLoS One
. 2020 Mar;
15(3):e0230526.
PMID: 32187209
Relapse of chronic lymphocytic leukaemia and non-Hodgkin's lymphoma after standard of care treatment is common and new therapies are needed. The targeted alpha therapy with 212Pb-NNV003 presented in this study...
4.
Pichard A, Marcatili S, Karam J, Constanzo J, Ladjohounlou R, Courteau A, et al.
Leukemia
. 2019 Dec;
34(5):1315-1328.
PMID: 31836849
Some patients with B-cell non-Hodkin lymphoma Lymphoma (NHL) become refractory to rituximab (anti-CD20 antibody) therapy associated with chemotherapy. Here, the effect of the anti-CD37 antibody-radionuclide conjugate lutetium-177 (Lu)-lilotomab (Betalutin) was...
5.
Maaland A, Heyerdahl H, OShea A, Eiriksdottir B, Pascal V, Andersen J, et al.
Eur J Nucl Med Mol Imaging
. 2019 Jul;
46(11):2311-2321.
PMID: 31309259
Purpose: The aim of this study was to explore the β-emitting lutetium-177 labelled anti-CD37 antibody NNV003 (Lu-NNV003, Humalutin®) for the treatment of non-Hodgkin's lymphoma in in vitro studies and in...
6.
Heyerdahl H, Roe K, Brevik E, Dahle J
Int J Radiat Oncol Biol Phys
. 2013 Jun;
87(1):153-9.
PMID: 23790511
Purpose: The purpose of this study was to investigate the effect of α-particle-emitting (227)Th-trastuzumab radioimmunotherapy on tumor vasculature to increase the knowledge about the mechanisms of action of (227)Th-trastuzumab. Methods...
7.
Heyerdahl H, Abbas N, Sponheim K, Mollatt C, Bruland O, Dahle J
Curr Radiopharm
. 2013 Apr;
6(2):106-16.
PMID: 23551111
Unlabelled: The aim of the current study was to investigate the therapeutic effect of 227Th-radioimmunotherapy on intraperitoneally growing human bioluminescent HER2 positive ovarian cancer cells. Methods: In vitro toxicity of...
8.
Abbas N, Heyerdahl H, Bruland O, Brevik E, Dahle J
Curr Radiopharm
. 2013 Apr;
6(2):78-86.
PMID: 23551110
Unlabelled: The aim of the present study was to compare the biodistribution, normal tissue toxicity and therapeutic effect of the alpha-particle emitting 227Th-trastuzumab and the beta-particle emitting 177Lu-trastuzumab in mice...
9.
Heyerdahl H, Abbas N, Brevik E, Mollatt C, Dahle J
PLoS One
. 2012 Aug;
7(8):e42345.
PMID: 22879947
Background: The aim of this study was to investigate therapeutic efficacy and normal tissue toxicity of single dosage and fractionated targeted alpha therapy (TAT) in mice with HER2-expressing breast and...
10.
Abbas N, Heyerdahl H, Bruland O, Borrebaek J, Nesland J, Dahle J
EJNMMI Res
. 2012 Jan;
1(1):18.
PMID: 22214432
Background: The aim of the present study was to explore the biodistribution, normal tissue toxicity, and therapeutic efficacy of the internalizing low-dose rate alpha-particle-emitting radioimmunoconjugate 227Th-trastuzumab in mice with HER2-expressing...